With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors

Neurocrine's stock price took a tumble Friday after the company revealed its 2025 revenue forecast for its 2017-approved tardive dyskinesia med Ingrezza.

Related Posts

Regulatory tracker: Eisai's Alzheimer's drug Leqembi re...

Mar 3, 2025  0

CDMO Axplora reveals €50M expansion at French productio...

Feb 13, 2025  0

Bristol Myers Squibb notches overall survival win with ...

Feb 19, 2025  0

Comments

Name

Email

Comment

Post Comment